Puma Biotechnology Quarterly Cash Flow Statement
NASDAQ: PBYIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Puma Biotechnology free cash flow
In the quarter ended Jun 30, 2026, Puma Biotechnology generated $1.6 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of $1.6 million, a free-cash-flow margin of 2.9% of revenue. Free cash flow was down 88.5% from the prior year's $14.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Puma Biotechnology cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 8.19M | -3.75M | 13.44M | 8.84M | 5.86M | 2.97M | 19.30M | 20.32M | -4.53M | -4.82M | 12.27M | 5.80M |
| Net Income growth (YoY) | +39.86% | -226.19% | -30.39% | -56.47% | — | — | +57.36% | +250.53% | -313.03% | -443.68% | — | — |
| Depreciation & Amortization | 2.52M | 2.58M | 2.66M | 2.72M | 2.76M | 2.80M | 2.84M | 2.88M | 2.91M | 2.90M | 2.89M | 2.88M |
| Stock-Based Compensation | 1.95M | 1.90M | 1.62M | 1.67M | 1.63M | 2.03M | 1.75M | 2.05M | 2.06M | 2.38M | 2.43M | 2.54M |
| Change in Working Capital | -17.42M | 27.26M | -17.46M | -7.37M | -818.00K | 7.12M | 14.98M | -26.11M | -751.00K | 25.20M | -18.80M | 1.53M |
| Operating Cash Flow | 1.62M | 15.42M | 14.42M | 9.69M | 14.08M | 3.61M | 15.61M | 11.04M | 1.03M | 11.25M | 10.46M | 10.62M |
| Capital Expenditures | 0 | 0 | 36.00K | -26.00K | -20.00K | -61.00K | -16.00K | -20.00K | -20.00K | 0 | -45.00K | -27.00K |
| Investing Cash Flow | 7.97M | 2.47M | -26.98M | 506.00K | -11.25M | 1.53M | -2.32M | 259.00K | 703.00K | -19.08M | -8.17M | 11.18M |
| Debt Repaid | -11.12M | -11.11M | -11.11M | -11.11M | -11.11M | -11.11M | -11.11M | -11.11M | -11.11M | 0 | 0 | 0 |
| Financing Cash Flow | -11.34M | -11.33M | -11.33M | -11.33M | -11.20M | -11.33M | -11.33M | -11.18M | -11.33M | 0 | 0 | 0 |
| Net Change in Cash | -1.75M | 6.56M | -23.89M | -1.14M | -8.37M | -6.19M | 1.96M | 114.00K | -9.60M | -7.83M | 2.29M | 21.79M |
| Free Cash Flow | 1.62M | 15.42M | 14.46M | 9.66M | 14.06M | 3.55M | 15.59M | 11.02M | 1.01M | 11.25M | 10.41M | 10.59M |
This table shows 12 quarterly periods of Puma Biotechnology's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PBYI's reporting calendar. What is a cash flow statement?